HERON THERAPEUTICS, INC. /DE/ (HRTX) Operating income 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) annual operating income history from SEC filings — each fiscal year as reported.
-$2.5MFY2025 · since FY2016: -$170.9M → -$2.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.5M | +78.0% |
| FY2024 | -$11.5M | +89.6% |
| FY2023 | -$110.6M | +36.7% |
| FY2022 | -$174.7M | +19.8% |
| FY2021 | -$217.8M | +4.5% |
| FY2020 | -$228.2M | -8.3% |
| FY2019 | -$210.7M | -14.5% |
| FY2018 | -$183.9M | +5.5% |
| FY2017 | -$194.6M | -13.8% |
| FY2016 | -$170.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Gross marginHRTX Operating marginHRTX Operating cash flowHRTX Free cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →